Alnylam Pharmaceuticals, Inc.
ALNY
$0.00
-3.01%
Alnylam Pharmaceuticals is a biotechnology company focused on RNA interference (RNAi) therapeutics. It is a leader in the RNAi field, leveraging its proprietary platform to develop and commercialize treatments for rare genetic diseases.
ALNY
Alnylam Pharmaceuticals, Inc.
$0.00
Investment Opinion: Should I buy ALNY Today?
Based on a synthesis of the data, the objective assessment is a Hold. The bullish case is supported by explosive revenue growth, a leading technological platform, and strong forward earnings estimates. However, the bearish case is equally compelling, citing an extreme trailing valuation, high debt, and a broken technical picture. The stock appears to be in a transition phase where future growth is anticipated but not yet fully realized in sustainable profits, making it a high-risk proposition at current levels. Investors should await either a more attractive valuation entry point or clearer signs of consistent bottom-line growth.
Sign up to view all
ALNY 12-Month Price Forecast
The data presents a stark contradiction: phenomenal fundamental growth is paired with severe technical weakness and a sky-high trailing valuation. The forward estimates provide a bridge to justification, but the path is fraught with execution risk. The neutral stance reflects this high uncertainty balanced against clear growth potential.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Alnylam Pharmaceuticals, Inc.'s 12-month outlook, with a consensus price target around $0.00 and implied upside of — versus the current price.
Average Target
$0.00
9 analysts
Implied Upside
—
vs. current price
Analyst Count
9
covering this stock
Price Range
$0 - $0
Analyst target range
Wall Street analyst sentiment is predominantly positive, with recent actions from firms like HC Wainwright, Chardan Capital, and Freedom Capital Markets reiterating or upgrading to 'Buy' ratings. While specific consensus target prices are not provided in the data, the forward earnings estimates average $19.21 per share, indicating strong expected growth from the current trailing EPS of $0.006.
Bulls vs Bears: ALNY Investment Factors
Alnylam presents a classic high-growth, high-risk biotech profile. The company's fundamentals are improving dramatically with strong revenue growth and a path to profitability, but the stock is burdened by a lofty valuation and a severe technical downtrend. The investment thesis hinges on the company's ability to deliver on its high forward earnings expectations.
Bullish
- Strong Revenue Growth: Q4 2025 revenue grew 85% YoY, showing robust commercial execution.
- Positive Analyst Sentiment: Multiple firms have reiterated or upgraded to 'Buy' ratings.
- High Expected Earnings Growth: Forward P/E of 23.3 suggests significant anticipated EPS expansion.
- Leader in RNAi Therapeutics: Proprietary platform and multiple commercial products provide a moat.
Bearish
- Extreme Valuation on Trailing Basis: Trailing P/E of 166.0 is exceptionally high, pricing in perfection.
- Elevated Debt Levels: Debt-to-equity ratio of 1.62 indicates significant financial leverage.
- Pronounced Technical Downtrend: Stock is down 28% over six months with sustained selling pressure.
- Volatile Profitability: Recent quarters show swings between net income and net loss.
ALNY Technical Analysis
The stock has been in a pronounced downtrend over the past six months, declining 28.2% from its highs in October 2025. The 1-month performance shows a slight decline of 0.6%, while the 3-month performance is significantly worse, down 16.8%, indicating sustained selling pressure. Currently trading at $330.87, the price is well below its 52-week high of $495.55 but remains above its 52-week low of $205.87, positioning it in the lower half of its annual range.
Beta
0.38
0.38x market volatility
Max Drawdown
-37.6%
Largest decline past year
52-Week Range
$206-$496
Price range past year
Annual Return
+19.5%
Cumulative gain past year
| Period | ALNY Return | S&P 500 |
|---|---|---|
| 1m | +0.1% | -4.3% |
| 3m | -20.3% | -4.0% |
| 6m | -30.1% | -2.0% |
| 1y | +19.5% | +22.2% |
| ytd | -20.3% | -3.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ALNY Fundamental Analysis
Revenue for Q4 2025 was $1.10 billion, representing a strong year-over-year growth of 84.95%. However, profitability has been volatile, with Q4 net income at $186 million (a 16.99% net margin), following a net loss in the prior-year quarter. The company's debt-to-equity ratio is elevated at 1.62, indicating significant leverage, but it maintains a strong current ratio of 2.76 and generated $465 million in trailing twelve-month free cash flow, suggesting adequate liquidity.
Quarterly Revenue
$1.1B
2025-12
Revenue YoY Growth
+0.84%
YoY Comparison
Gross Margin
+0.75%
Latest Quarter
Free Cash Flow
$465383000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ALNY Overvalued?
Given the company's positive net income, the trailing P/E ratio is the primary valuation metric, which is extremely high at 166.0. This elevated multiple reflects high growth expectations for its RNAi platform and commercial products. For comparison, the forward P/E is a more moderate 23.3, suggesting analysts anticipate significant earnings growth in the coming year.
PE
166.0x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -456x~71x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
92.8x
Enterprise Value Multiple
Investment Risk Disclosure
The primary risk is valuation. With a trailing P/E of 166 and a Price/Sales of 14, the stock is priced for near-flawless execution of its growth strategy. Any stumble in revenue growth, clinical trial results, or margin expansion could trigger a significant de-rating. Financial risk is also notable due to the elevated debt-to-equity ratio of 1.62, which increases vulnerability to rising interest rates or cash flow disruptions. Furthermore, the stock exhibits high idiosyncratic volatility, as evidenced by a 37.6% max drawdown and a beta of 0.38, indicating it moves independently of the broader market, often to the downside recently. The high short ratio of 4.2 underscores persistent skepticism in the market, which can fuel sharp declines on negative news.
FAQ
Key risks include valuation collapse if growth slows (P/E of 166), high financial leverage (Debt/Equity of 1.62), and volatile quarterly profits. The stock is also in a pronounced downtrend, down 28% in six months, and faces high short interest (Short Ratio 4.2), which can amplify declines. Execution risk on its lofty forward EPS estimates is paramount.
The 12-month outlook is mixed with a base case target range of $330-$400, aligning with its current price and forward P/E. The bull case ($450-$495) depends on flawless execution of its $19+ EPS target. The bear case ($205-$300) risks a re-test of lows if growth disappoints. The AI assessment assigns a 50% probability to the base case, 30% to bull, and 20% to bear.
Based on trailing metrics, ALNY appears significantly overvalued with a P/E of 166 and a P/S of 14. However, the forward P/E of 23.3, based on estimated EPS of $19.21, suggests the market expects massive earnings growth to justify the current price. The stock is priced for future perfection, making it vulnerable if those expectations are not met.
ALNY is a high-risk, high-potential stock. Its 85% YoY revenue growth and leadership in RNAi therapeutics are strong positives. However, with a trailing P/E of 166 and a 28% price decline over six months, it is not a clear-cut buy. It may be suitable for aggressive growth investors comfortable with volatility, but most should consider it a Hold until profitability stabilizes.
ALNY is primarily suitable for long-term investment. The company's value proposition is based on the multi-year success of its RNAi platform and pipeline. The extreme volatility and high valuation multiples make it a poor candidate for short-term trading. Investors should have a horizon of 3-5 years to allow the growth story to fully unfold and mitigate interim price swings.